ClinicalTrials.gg
CompletedNCT01429064Updated Feb 20, 2017Results posted

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

A Phase 2 interventional study of ODM-201 in Prostate Cancer, sponsored by Orion Corporation, Orion Pharma. Completed at 17 sites in 6 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-20.

Sponsored by Orion Corporation, Orion Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Enrollment
32nd of 59
76 · median 80
Started
2011
with 1 other
Phase 2
29 of 59
16 open now
Registered
2nd of 59
by date
Lead sponsor
3 of 59
Orion Corporation, Orion Pharma

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 32nd largest by enrollment, is one of 2 that started in 2011, is one of 29 in phase 2, and was the 2nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Successful completion of study protocol 3104001
  • Response or stable disease in study 3104001 at week 12

Exclusion criteria

Exclusion Criteria:

  • New serious concurrent medical condition
  • Not able to swallow the study drug
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    ODM-201

    Drug: ODM-201

Interventions

  • ODM-201 administered orally daily

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Adverse events from start of ODM-201 treatment (in ARADES 3104001 study) until end of study visit (in ARADES-EXT 3104002 study). Median duration on study treatment was 11,0 months.

    Time frame: From first dose of study treatment up to 4 weeks after last dose of study treatment

07

Results

Posted Dec 22, 2016

Participant flow

Participants were enrolled at 17 hospitals in Europe and in the USA

Participant flow — Overall Study
MilestonePatients From Arades 3104001 Dose EscalationPatients From Arades 3104001 Dose Expansion (200mg/Day)Patients From Arades 3104001 Dose Expansion (400mg/Day)Patients From Arades 3104001 Dose Expansion (1400mg/Day)
Started19221916
Completed19221916
Not completed0000

Outcome measures

PrimaryNumber of Participants With Adverse Events

Adverse events from start of ODM-201 treatment (in ARADES 3104001 study) until end of study visit (in ARADES-EXT 3104002 study). Median duration on study treatment was 11,0 months.

Time frame:
From first dose of study treatment up to 4 weeks after last dose of study treatment
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsPatients From Arades 3104001 Dose EscalationPatients From Arades 3104001 Dose Expansion (200mg/Day)Patients From Arades 3104001 Dose Expansion (400mg/Day)Patients From Arades 3104001 Dose Expansion (1400mg/Day)
Number of Participants With Adverse Events19221916

Adverse events

Collected over From first dose of study treatment up to 4 weeks after last dose of study treatment. Median duration on study treatment was 11,0 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients From Arades 3104001 Dose Escalation—5/19 (26.3%)19/19 (100%)
Patients From Arades 3104001 Dose Expansion (200mg/Day)—7/22 (31.8%)22/22 (100%)
Patients From Arades 3104001 Dose Expansion (400mg/Day)—3/19 (15.8%)19/19 (100%)
Patients From Arades 3104001 Dose Expansion (1400mg/Day)—4/16 (25%)16/16 (100%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventPatients From Arades 3104001 Dose EscalationPatients From Arades 3104001 Dose Expansion (200mg/Day)Patients From Arades 3104001 Dose Expansion (400mg/Day)Patients From Arades 3104001 Dose Expansion (1400mg/Day)
Back painMusculoskeletal and connective tissue disorders0/190/221/192/16
Acute kidney injuryRenal and urinary disorders0/192/220/190/16
NauseaGastrointestinal disorders0/190/220/191/16
ChillsGeneral disorders0/190/220/191/16
PyrexiaGeneral disorders0/191/220/191/16
PneumoniaInfections and infestations0/190/220/191/16
UrosepsisInfections and infestations0/191/220/191/16
Enterobacter test positiveInvestigations0/190/220/191/16
Muscular weaknessMusculoskeletal and connective tissue disorders0/190/220/191/16
Urinary incontinenceRenal and urinary disorders0/190/220/191/16
Most frequent other events
Showing 10 of 202
Most frequent other events
EventPatients From Arades 3104001 Dose EscalationPatients From Arades 3104001 Dose Expansion (200mg/Day)Patients From Arades 3104001 Dose Expansion (400mg/Day)Patients From Arades 3104001 Dose Expansion (1400mg/Day)
FatigueGeneral disorders5/193/225/198/16
DiarrhoeaGastrointestinal disorders9/190/222/191/16
Back painMusculoskeletal and connective tissue disorders7/194/225/196/16
PainGeneral disorders4/197/221/193/16
ArthralgiaMusculoskeletal and connective tissue disorders6/197/223/193/16
Oedema peripheralGeneral disorders3/192/221/195/16
NauseaGastrointestinal disorders5/192/223/193/16
AstheniaGeneral disorders5/191/222/190/16
Decreased appetiteMetabolism and nutrition disorders1/193/225/192/16
NasopharyngitisInfections and infestations4/192/221/191/16

Baseline characteristics

Safety

Age, Continuous
Age, Continuous(years)Patients From Arades 3104001 Dose EscalationPatients From Arades 3104001 Dose Expansion (200mg/Day)Patients From Arades 3104001 Dose Expansion (400mg/Day)Patients From Arades 3104001 Dose Expansion (1400mg/Day)Total
Mean68.8 ± 6.166.5 ± 6.668.9 ± 8.374.6 ± 6.369.4 ± 7.3
Gender
Gender(Participants)Patients From Arades 3104001 Dose EscalationPatients From Arades 3104001 Dose Expansion (200mg/Day)Patients From Arades 3104001 Dose Expansion (400mg/Day)Patients From Arades 3104001 Dose Expansion (1400mg/Day)Total
Female00000
Male1922191676
08

Study locations

17 sites
  • The Urology Center of Colorado
    Wheat Ridge, Colorado 80211, United States
  • Eastern CT Hematology and Oncology Associates
    Norwich, Connecticut 06360, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Klinika onkologie a radioterapie LFUK a FN
    Hradec Králové, Czech Republic
  • East-Tallinn Central Hospital
    Tallinn, Estonia
  • Helsinki University Central Hospital
    Helsinki, Finland
  • Kuopio University Hospital
    Kuopio, Finland
  • Oulu University Hospital
    Oulu, Finland
  • Tampere University Hospital
    Tampere, Finland
  • Turku University Hospital
    Turku, Finland
  • Saint Louis Hospital
    Paris, France
  • Institut Gustave Roussy
    Villejuif, France
  • Queen Elizabeth Hospital
    Birmingham, United Kingdom
  • Velindre Cancer Centre
    Cardiff, United Kingdom
  • Christie Hospital
    Manchester, United Kingdom
  • Churchill Hospital
    Oxford, United Kingdom
09

References and documents

Publications

  • Shore ND, Tammela TL, Massard C, Bono P, Aspegren J, Mustonen M, Fizazi K. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naive and CYP17 Inhibitor-naive Patients: Follow-up from the ARADES and ARAFOR Trials. Eur Urol Focus. 2018 Jul;4(4):547-553. doi: 10.1016/j.euf.2017.01.015. Epub 2017 Feb 14. PubMed 28753851 ↗
  • Fizazi K, Massard C, Bono P, Kataja V, James N, Tammela TL, Joensuu H, Aspegren J, Mustonen M. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naive Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. Eur Urol Focus. 2017 Dec;3(6):606-614. doi: 10.1016/j.euf.2017.01.010. Epub 2017 Feb 27. PubMed 28753849 ↗
  • Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M; ARADES study group. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014 Aug;15(9):975-85. doi: 10.1016/S1470-2045(14)70240-2. Epub 2014 Jun 25. PubMed 24974051 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2011
First posted
Sep 5, 2011
Start
Jun 2011
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results first posted
Dec 22, 2016
Last update
Feb 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01429064
Responsible party
Sponsor
First posted
Sep 5, 2011
Start date
Jun 2011
Primary completion
Nov 2015
Completion
Nov 2015
Results posted
Dec 22, 2016
Last update
Feb 20, 2017

Study contacts

Karim Fizazi
principal investigator · Gustave Roussy, Cancer Campus, Grand Paris

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darolutamide

Start the discussion